Why American Capital Ltd., Alnylam Pharmaceuticals Inc., and Micron Technology Inc. are Today's 3 Best Stocks

Comments from Fed Chairwoman Janet Yellen help stocks across the market rise

Mar 31, 2014 at 5:15PM

Daily FoolReassuring comments from Federal Reserve Chairwoman Janet Yellen helped the S&P 500 (SNPINDEX:^GSPC) race to a 0.8% gain on the last day of March. The index closed at just over 1,872, capping off a so-so month for the markets. Still, it's been a great run for the S&P 500 after the downbeat start to the year: Since early February, the index has picked up more than 7% and has investors feeling much more confident about the market's momentum.

Speaking in Chicago today, Yellen cited ongoing weakness in the American economic picture even with the recent recovery in the jobs market. Investors inferred that Yellen's reference to weak wage growth and declining labor force participation, among other matters, allows for plenty more room for the Fed to continue its post-recession history of low interest rates.

We'll get a much better picture of just how well the economy is rolling along come Friday, when the Department of Labor is set to release the jobs report for March. Economists on average predict a gain of about 200,000 jobs this month, which would improve substantially on February's 175,000-job gain.

Still, the S&P 500 and the market's biggest gainers weren't looking too far ahead today. American Capital (NASDAQ:ACAS) shares jumped higher by 11.2% on a day of few huge movers on the market, while biotech stock Alnylam Pharmaceuticals (NASDAQ:ALNY) climbed 9.7%. Among larger-cap stocks, Micron Techology (NASDAQ:MU) shares gained more than 7.5%.

American Capital shareholders announced that it had repurchased 8.9 million of its shares in the first quarter; more importantly, the business developer is halting its share repurchase program. The stock has shed more than 1% over the past year despite the market's great gains. As fellow Fool analyst Jordan Wathen notes, American Capital's buyback plan hasn't helped the company trade at a higher value, and its lack of a dividend puts it a disadvantage against the competition. Ending a plan that hasn't paid off and pursuing a more aggressive course of maximizing its value could be the company's next step from here.

Alnylam bounced back today in a relief to investors who have weathered a terrible month from this developmental biotech stock.

Alnylam

Despite a huge gain over the past year, Alnylam's shares have collapsed by more than 22% in the past month. That hasn't waved off interest from Big Pharma: Just this past week, Sanofi's (NYSE:SNY) Genzyme unit invested a further $23 million into the company, bolstering its original $700 million investment. Alnylam's clinical-stage transthyretin-mediated amyloidosis treatment patisiran is the drug furthest along in the company's pipeline, having entered phase 3 trials last November after scoring strong phase 2 results. It'll be a while before any conclusive findings emerge from late-stage studies, but keep an eye on the drug: J.P. Morgan projected in January that patisiran, if approved, could evenually rake in $700 million in peak sales annually.

Finally, Micron hit a high today among bigger-name stocks ahead of its earnings release this Thursday. While Micron made news for being added to the growth stock index Barron's 400, investors likely are looking forward to the company's results. Analysts project a big turnaround from last year, when the company reported a $0.28 per-share loss in the quarter ending Feb. 14. Analysts on average project earnings per share of $0.74 for this quarter. If Micron can ward off concerns over the possibility of falling prices in the memory market and capitalize on demand from the mobile market, it could surprise investors.

The 1 under-the-radar stock that could transform your financial future
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. The Motley Fool owns shares of JPMorgan Chase. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers